Gujarat Magazine

Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio

 Breaking News
  • No posts were found

Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio

April 03
10:46 2024
Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Anemia In Chronic Kidney Disease pipeline constitutes 10+ key companies continuously working towards developing 10+ Anemia In Chronic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Anemia In Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Anemia In Chronic Kidney Disease Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease Market.

 

Some of the key takeaways from the Anemia In Chronic Kidney Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Anemia In Chronic Kidney Disease treatment therapies with a considerable amount of success over the years. 
  • Anemia In Chronic Kidney Disease companies working in the treatment market are Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others, are developing therapies for the Anemia In Chronic Kidney Disease treatment 
  • Emerging Anemia In Chronic Kidney Disease therapies in the different phases of clinical trials are- DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others are expected to have a significant impact on the Anemia In Chronic Kidney Disease market in the coming years.   
  • In March 2024, Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Vafseo® (vadadustat) Tablets. This medication is indicated for the treatment of anemia resulting from chronic kidney disease (CKD) in adults undergoing dialysis for a minimum of three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor administered once daily, which triggers the body’s response to hypoxia to stimulate natural erythropoietin production, thereby managing anemia. Vafseo has received approval in 37 countries.
  • In April 2023, The Phase 3 clinical trial of GX-E4 (Efepoetin alfa), a potential treatment for anaemia brought on by chronic kidney disease, has revealed preliminary results, according to Genexine and its Asian regional partner, KG Bio. At the World Congress of Nephrology (WCN2023), its noninferiority results in comparison to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were reported. 

 

Anemia In Chronic Kidney Disease Overview

A frequent side effect of chronic kidney disease (CKD) is anaemia. renal disease (CKD) is characterised by impaired blood filtration due to renal injury. Waste and fluid might accumulate in the body as a result of this injury. Additional health issues can result from CKD.

 

Get a Free Sample PDF Report to know more about Anemia In Chronic Kidney Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-pipeline-insight

 

Emerging Anemia In Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

  • DDO-3055: Jiangsu HengRui Medicine
  • DISC 0974: Disc Medicine
  • SSS 17: 3SBio
  • AND017: Kind Pharmaceuticals
  • Pegol-Sihematide: Jiangsu Hansoh Pharmaceuticals
  • Efepoetin alfa: Genexine

 

Anemia In Chronic Kidney Disease Route of Administration

Anemia In Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Anemia In Chronic Kidney Disease Molecule Type

Anemia In Chronic Kidney Disease Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Anemia In Chronic Kidney Disease Pipeline Therapeutics Assessment

  • Anemia In Chronic Kidney Disease Assessment by Product Type
  • Anemia In Chronic Kidney Disease By Stage and Product Type
  • Anemia In Chronic Kidney Disease Assessment by Route of Administration
  • Anemia In Chronic Kidney Disease By Stage and Route of Administration
  • Anemia In Chronic Kidney Disease Assessment by Molecule Type
  • Anemia In Chronic Kidney Disease by Stage and Molecule Type

 

DelveInsight’s Anemia In Chronic Kidney Disease Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Anemia In Chronic Kidney Disease product details are provided in the report. Download the Anemia In Chronic Kidney Disease pipeline report to learn more about the emerging Anemia In Chronic Kidney Disease therapies

 

Some of the key companies in the Anemia In Chronic Kidney Disease Therapeutics Market include:

Key companies developing therapies for Anemia In Chronic Kidney Disease are – FibroGen Inc, FortuneRock (China) Ltd, General Biologics Inc, Genexine Inc, Great Bay Bio Holdings Ltd, GSK plc, 3SBio Inc, Akebia Therapeutics Inc, Avesthagen Ltd, Biocad, Chong Kun Dang Pharmaceutical Corporation, Dong-A Socio Holdings Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Liminal BioSciences Inc, Panacea Biotec Ltd, Panion & Bf Biotech Inc, PharmaEssentia Corp, PhytoHealth Corp, Jiangsu Hansoh Pharmaceutical Group Co Ltd, UBI Pharma Inc, Uni-Bio Science Group Ltd, Xenetic Biosciences Inc, Zosano Pharma Corp, Shanghai Chemo Wanbang Biopharma Co Ltd, SunBio Inc, HEC Pharma Co Ltd, HK inno.N Corp, Imagine Pharma LLC, InSilico Medicine, Japan Tobacco Inc, Jecho Biopharmaceuticals Co Ltd, Zydus Lifesciences Ltd, and others.

 

Anemia In Chronic Kidney Disease Pipeline Analysis:

The Anemia In Chronic Kidney Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Anemia In Chronic Kidney Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anemia In Chronic Kidney Disease Treatment.
  • Anemia In Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Anemia In Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anemia In Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Anemia In Chronic Kidney Disease drugs and therapies

 

Anemia In Chronic Kidney Disease Pipeline Market Drivers

  • Increase in the geriatric population with a higher risk of renal anemia due to age-related renal issues, increase in research and developmental activities are some of the important factors that are fueling the Anemia In Chronic Kidney Disease Market.

 

Anemia In Chronic Kidney Disease Pipeline Market Barriers

  • However, high-cost associated with the disease, side effects associated with the disease and other factors are creating obstacles in the Anemia In Chronic Kidney Disease Market growth.

 

Scope of Anemia In Chronic Kidney Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Anemia In Chronic Kidney Disease Companies: Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others
  • Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others
  • Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia In Chronic Kidney Disease current marketed and Anemia In Chronic Kidney Disease emerging therapies
  • Anemia In Chronic Kidney Disease Market Dynamics: Anemia In Chronic Kidney Disease market drivers and Anemia In Chronic Kidney Disease market barriers 

 

Request for Sample PDF Report for Anemia In Chronic Kidney Disease Pipeline Assessment and clinical trials

 

Table of Contents 

1. Anemia In Chronic Kidney Disease Report Introduction

2. Anemia In Chronic Kidney Disease Executive Summary

3. Anemia In Chronic Kidney Disease Overview

4. Anemia In Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment

5. Anemia In Chronic Kidney Disease Pipeline Therapeutics

6. Anemia In Chronic Kidney Disease Late Stage Products (Phase II/III)

7. Anemia In Chronic Kidney Disease Mid Stage Products (Phase II)

8. Anemia In Chronic Kidney Disease Early Stage Products (Phase I)

9. Anemia In Chronic Kidney Disease Preclinical Stage Products

10. Anemia In Chronic Kidney Disease Therapeutics Assessment

11. Anemia In Chronic Kidney Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Anemia In Chronic Kidney Disease Key Companies

14. Anemia In Chronic Kidney Disease Key Products

15. Anemia In Chronic Kidney Disease Unmet Needs

16 . Anemia In Chronic Kidney Disease Market Drivers and Barriers

17. Anemia In Chronic Kidney Disease Future Perspectives and Conclusion

18. Anemia In Chronic Kidney Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

Gong Fu Cha Tea Ceremony And Gongfu Tea Brewing

Read Full Article

Categories